Basile Stamatopoulos is associate professor at University of Brussels (ULB) and a PI in the Laboratory of Clinical Cell Therapy of Dr Laurence Lagneaux, part of the Department of Hematology of Jules Bordet Institute (Brussels, Belgium). He is a molecular biologist and completed his PhD in biomedical and pharmaceutical sciences in University of Brussels (ULB, Belgium) on the physiopathology, the prognostic factors and the new treatment strategies of Chronic Lymphocytic Leukemia (CLL). During his thesis, he published several papers in high level hematology journal (Stamatopoulos et al, Clinical Chemistry 2007, Leukemia 2008, Leukemia 2009, Haematologica 2009, Blood 2009). The group of Basile Stamatopoulos is particularly interested in the interaction between leukemic cells with the cells of their microenvironment. During his post-doc in University of Paris XIII (France), he developed new strategies to disrupt the cross-talk between leukemic cells and a stromal microenvironment (Stamatopoulos et al, Haematologica 2010, Haematologica 2012). From 2014 to 2016, he completed his training in the Molecular Diagnostic Center of Oxford University (United Kingdom) where he learned new technics such as next generation sequencing (Stamatopoulos et al, Leukemia 2017, Clinical Cancer Research 2018). Since 2012, Dr Stamatopoulos is working on extracellular vesicles and how these vesicles play a role in the communication between leukemic cells and a stromal and immune microenvironment. In 2017, his team demonstrated that stromal EVs can protect leukemic cells from apoptosis, increase their migration properties, decrease their chemo-resistance and change their gene expression profiles (Crompot et al, Haematologica 2017). His current project focuses on microRNA carried by leukemic EVs and how they can manipulate the immune microenvironment.